Impact of antimicrobial use on the epidemiology of nosocomial infections on the oncology ward: Implications for infection control

Cancer Investigation

Volumn 16, Issue 4, 1998, Pages 263-268

  Currie, Brian R ^a,b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMICROBIAL THERAPY; BONE MARROW TRANSPLANTATION; CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; PRIORITY JOURNAL; REVIEW;

EID: 0031953994     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909809039776     Document Type: Review

References (28)

1. Koll BS, Brown AE: The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 17 (Suppl 2): S322-S328, 1993.
2. Hughes WT, Flynn PM, Williams BG. Nosocomial infection in patients with neoplastic diseases. In: Hospital Epidemiology and Infection Control, edited by Mayhall CG. Baltimore, William & Wilkins, 1996, pp 618-631.
3. Carlisle PS, Gucalp R, Wiernik PH: Nosocomial infections in neuropenic cancer patients. Infect Control Hosp Epidemiol 14:320-324, 1993.
4. Haley RW, Culver DH, White JW, et al: The efficacy of infection surveillance and control programs in preventing nosocomial infections in U.S. hospitals. Am J Epidemiol 121:182-205, 1985.
5. Eickhoff TC: Antibiotics and nosocomial infections. In: Hospital Infections, 3rd ed, edited by Bennett JV, Brachman PS, Boston, Little, Brown and Company, 1992, pp 245-264.
6. Whimbey E, Kiehn TE, Brannon P, et al: Bacteremia and fungemia complicating neoplastic disease. Am J Med 82:723-730, 1987.
7. Del Favero A, Menchetti F, Bucaneve G, et al: Septicaemia due to gram-positive cocci in cancer patients. J Antimicrob Chemother 21 (Suppl C): 157-162, 1988.
8. Viscoli C, Van der Auwera P, Meunier F: Gram-positive infections in granulocytopenic patients: an important issue? J Antimicrob Chemother 21 (Suppl C): 149-156, 1988.
9. Awada A, Van der Auwera P, Meunier F, et al: Streptococcal and enterococcal bacteremia in patients with cancer. Clin Infect Dis 15:33-48, 1992.
10. Decker CF, Simon GL, Keiser JF: Flavimonas oryzihabitants (Pseudomonas oryzihabitans: CDC group Ve-2) bacteremia in the immunocompromised host. Arch Intern Med 15:603-604, 1991.
11. Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 12:997-1003, 1990.
12. Bodey GP, Elting LS, Rodriguez S: Bacteremia caused by Enterobacter. 15 years of experience in a cancer hospital. Rev Infect Dis 13:550-558, 1991.
13. Johnson MP, Ramphai R: β-Lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. J Infect Dis 162:981-983, 1990.
14. Samonis G, Anaissie E, Elting L, Bodey GP: Review of Citrobacter bacteremia in cancer patients over a sixteen-year period. Eur J Clin Microbiol Infect Dis 10:479-485, 1991.
15. Boyce JM: Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 3:901-913, 1989.
16. Montecalvo MA, Horowitz H, Gedris C, et al: Outbreak of vancomycin-, ampicillin-, and aminoglycoside-resistant Enterococcus faecium bacteremia in an adult oncology unit. Antimicrob Agents Chemother 38:1363-1367, 1994.
17. Edmond MB, Ober JF, Weinbaum DL, et al: Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection. Clin Infect Dis 20:1126-1133, 1995.
18. Woodford N, Johnson AP, Morrison D, et al: Current perspectives on glycopeptide resistance. Clin Microbiol Rev 8:585-615, 1995.
19. Centers for Disease Control and Prevention: Recommendations for preventing the spread of vancomycin resistance. Infect Control Hosp Epidemiol 16:105-113, 1995.
20. Morris JG, Shay DK, Hebden JN, et al: Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center. Ann Intern Med 123:250-259, 1995.
21. Chew D, Currie B, Levi MH: Antimicrobial susceptibility of vancomycin-resistant enterococci (VRE) to standard and alternative antimicrobial agents. Infect Control Hosp Epidemiol 16:46, 1995 (abstract).
22. Wells CL, Juni BA, Cameron SB, et al: Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 21:45-50, 1995.
23. Currie BP, Gnass S, Levi MH: Hospital based rectal swab culture survey to detect vancomycin-resistant enterococci: Utility and application. Int J Infect Dis 1:87-91, 1996.
24. Montecalvo MA, de Lencastre H, Carraher M, et al.: Natural history of colonization with vancomycin-resistant Enter-s ococcus faecium. Infect Control Hosp Epidemiol 16:680-685, 1995.
25. Shay DK, Maloney SA, Montecalvo M, et al: Epidemiology and mortality risk of vancomycin-resistant enterococcal blood stream infections. J Infect Dis 172:993-1000, 1995.
26. Wingard JR: Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 20:115-125, 1995.
27. Perfect JR, Schell WA: The new fungal opportunities are coming. Clin Infect Dis 22(Suppl 2):S112-S118, 1996.
28. Pfaller MA: Nosocomial candidiasis: Emerging species, reservoirs, and modes of transmission. Clin Infect Dis 22(Suppl 2):S89-S94, 1996.